MedTrace Logo

Multiple-Dose Study of VGX-1027 in Healthy Subjects

NCT00760396 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-04-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety profile, tolerability and pharmacokinetics following multiple oral doses of 40mg to 200mg VGX 1027 in healthy subjects administered for 5 days.

Conditions

  • Healthy

Interventions

DRUG

VGX-1027

Subjects will

Sponsors & Collaborators

  • GeneOne Life Science, Inc.

    collaborator INDUSTRY

  • VGX Pharmaceuticals, LLC

    lead INDUSTRY

Principal Investigators

  • Stephan A Bart, MD · SNBL Clinical Pharmacology Center, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-11-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760396 on ClinicalTrials.gov